Table 1:
Baseline clinical characteristics of the DFCI population. See also Table S3.
| DFCI (n=1840) | ||
|---|---|---|
|
| ||
| N (median) | % (range) | |
| Age at ICI start | 65 | 22–93 |
|
| ||
| Tumor Type | ||
| CRC | 78 | 4.2 |
| EGC | 144 | 7.8 |
| HNSCC | 100 | 5.4 |
| Melanoma | 314 | 17.1 |
| Non-small cell lung carcinoma | 879 | 47.8 |
| RCC | 155 | 8.4 |
| Urothelial Carcinoma | 170 | 9.2 |
|
| ||
| Sex | ||
| Male | 1071 | 58.2 |
| Female | 769 | 41.8 |
|
| ||
| Site of specimen sequenced | ||
| Primary | 871 | 47.3 |
| Metastatic | 950 | 51.6 |
| Unspecified | 19 | 1.0 |
|
| ||
| Genetic Ancestry | ||
| African | 83 | 4.5 |
| Asian | 90 | 4.9 |
| Europeans | 1667 | 90.6 |
|
| ||
| Self-Reported Race | ||
| African Americans | 60 | 3.3 |
| Asians | 70 | 3.8 |
| Whites | 1646 | 89.5 |
| Other | 64 | 3.5 |
|
| ||
| ICI type | ||
| Single | 1300 | 70.7 |
| Combination | 540 | 29.3 |
|
| ||
| ICI class | ||
| Anti-PD-1/PD-L1 | 1577 | 85.7 |
| Anti-CTLA-4 | 33 | 1.8 |
| Anti-PD-1/PD-L1 + anti-CTLA-4 | 230 | 12.5 |
|
| ||
| Number of prior lines | ||
| 0 | 919 | 49.9 |
| 1 | 595 | 32.3 |
| ≥2 | 326 | 17.7 |